| [1] |
徐勇明，王宏勤. MicroRNA调控胶质瘤替莫唑胺化疗耐药的研究进展[J]. 中华神经创伤外科电子杂志, 2016, 2(4): 241-244.
|
| [2] |
Tabibkhooei A, Izadpanahi M, Arab A, et al. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas[J]. Clin Neurol Neurosurg, 2020, 190: 105652.
|
| [3] |
Shi R, Wang PY, Li XY, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients[J]. Oncotarget, 2015, 6(29): 26971-26981.
|
| [4] |
Guo X, Qiu W, Wang J, et al. Glioma exosomes mediate the expansion and function of myeloid-derived suppressor cells through microRNA-29a/Hbp1 and microRNA-92a/Prkar1a pathways[J]. Int J Cancer, 2019, 144(12): 3111-3126.
|
| [5] |
Guo X, Qiu W, Liu Q, et al. Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways[J]. Oncogene, 2018, 37(31): 4239-4259.
|
| [6] |
Wang ZF, Liao F, Wu H, et al. Glioma stem cells-derived exosomal miR-26a promotes angiogenesis of microvessel endothelial cells in glioma[J]. J Exp Clin Cancer Res, 2019, 38(1): 201.
|
| [7] |
Cai Q, Zhu A, Gong L. Exosomes of glioma cells deliver miR-148a to promote proliferation and metastasis of glioblastoma via targeting CADM1[J]. Bull Cancer, 2018, 105(7-8): 643-651.
|
| [8] |
Xu H, Zhao G, Zhang Y, et al. Mesenchymal stem cell-derived exosomal microRNA-133b suppresses glioma progression via Wnt/β-catenin signaling pathway by targeting EZH2[J]. Stem Cell Res Ther, 2019, 10(1): 381.
|
| [9] |
Yu L, Gui S, Liu Y, et al. Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2[J]. Aging (Albany NY), 2019, 11(15): 5300-5318.
|
| [10] |
Figueroa J, Phillips LM, Shahar T, et al. Exosomes from glioma-associated mesenchymal stem cells increase the tumorigenicity of glioma stem-like cells via transfer of miR-1587[J]. Cancer Res, 2017, 77(21): 5808-5819.
|
| [11] |
Yue X, Lan F, Xia T. Hypoxic glioma cell-secreted exosomal miR-301a activates wnt/β-catenin signaling and promotes radiation resistance by targeting TCEAL7[J]. Mol Ther, 2019, 27(11): 1939-1949.
|
| [12] |
Yin J, Zeng A, Zhang Z, et al. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma[J]. EBioMedicine, 2019, 42: 238-251.
|
| [13] |
Li Q, Wang AY, Xu QG, et al. In-vitro inhibitory effect of EGFL7-RNAi on endothelial angiogenesis in glioma[J]. Int J Clin Exp Pathol, 2015, 8(10): 12234-12242.
|
| [14] |
Molinaro AM, Taylor JW, Wiencke JK, et al. Genetic and molecular epidemiology of adult diffuse glioma[J]. Nat Rev Neurol, 2019, 15(7): 405-417.
|
| [15] |
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10): 987-996.
|
| [16] |
Alifieris C, Trafalis DT. Glioblastoma multiforme: pathogenesis and treatment[J]. Pharmacol Ther, 2015, 152: 63-82.
|
| [17] |
H Rashed M, Bayraktar E, K Helal G, et al. Exosomes: from garbage bins to promising therapeutic targets[J]. Int J Mol Sci, 2017, 18(3): 538.
|
| [18] |
Saadatpour L, Fadaee E, Fadaei S, et al. Glioblastoma: exosome and microRNA as novel diagnosis biomarkers[J]. Cancer Gene Ther, 2016, 23(12): 415-418.
|
| [19] |
Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers[J]. Nat Cell Biol, 2008, 10(12): 1470-1476.
|
| [20] |
Hallal S, Russell BP, Wei H, et al. Extracellular vesicles from neurosurgical aspirates identifies chaperonin containing TCP1 subunit 6A as a potential glioblastoma biomarker with prognostic significance[J]. Proteomics, 2019, 19(1-2): e1800157.
|
| [21] |
Williams N. Solvents in the workplace[J]. Occup Health (Lond), 1995, 47(5): 169-170.
|
| [22] |
Li CC, Eaton SA, Young PE, et al. Glioma microvesicles carry selectively packaged coding and non-coding RNAs which alter gene expression in recipient cells[J]. RNA Biol, 2013, 10(8): 1333-1344.
|
| [23] |
Chen X, Yang F, Zhang T, et al. MiR-9 promotes tumorigenesis and angiogenesis and is activated by MYC and OCT4 in human glioma[J]. J Exp Clin Cancer Res, 2019, 38(1): 99.
|
| [24] |
Santangelo A, Imbrucè P, Gardenghi B, et al. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker[J]. J Neurooncol, 2018, 136(1): 51-62.
|
| [25] |
Henriksen M, Johnsen KB, Olesen P, et al. MicroRNA expression signatures and their correlation with clinicopathological features in glioblastoma multiforme[J]. Neuromolecular Med, 2014, 16(3): 565-577.
|
| [26] |
Sun X, Ma X, Wang J, et al. Glioma stem cells-derived exosomes promote the angiogenic ability of endothelial cells through miR-21/VEGF signal[J]. Oncotarget, 2017, 8(22): 36137-36148.
|
| [27] |
Lang FM, Hossain A, Gumin J, et al. Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas[J]. Neuro Oncol, 2018, 20(3): 380-390.
|
| [28] |
van der Vos KE, Abels ER, Zhang X, et al. Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain[J]. Neuro Oncol, 2016, 18(1): 58-69.
|
| [29] |
Monteforte A, Lam B, Sherman MB, et al. Glioblastoma exosomes for therapeutic angiogenesis in peripheral ischemia[J]. Tissue Eng Part A, 2017, 23(21-22): 1251-1261.
|
| [30] |
Akers JC, Ramakrishnan V, Kim R, et al. miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients[J]. J Neurooncol, 2015, 123(2): 205-216.
|
| [31] |
Fareh M, Almairac F, Turchi L, et al. Cell-based therapy using miR-302-367 expressing cells represses glioblastoma growth[J]. Cell Death Dis, 2017, 8(3): e2713.
|
| [32] |
Tüzesi Á, Kling T, Wenger A, et al. Pediatric brain tumor cells release exosomes with a miRNA repertoire that differs from exosomes secreted by normal cells[J]. Oncotarget, 2017, 8(52): 90164-90175.
|
| [33] |
Deng SZ, Lai MF, Li YP, et al. Human marrow stromal cells secrete microRNA-375-containing exosomes to regulate glioma progression[J]. Cancer Gene Ther, 2020, 27(3-4): 203-215.
|
| [34] |
Shao N, Xue L, Wang R, et al. miR-454-3p is an exosomal biomarker and functions as a tumor suppressor in glioma[J]. Mol Cancer Ther, 2019, 18(2): 459-469.
|
| [35] |
Qian M, Wang S, Guo X, et al. Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-κB pathways[J]. Oncogene, 2020, 39(2): 428-442.
|
| [36] |
Katakowski M, Buller B, Zheng X, et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth[J]. Cancer Lett, 2013, 335(1): 201-204.
|
| [37] |
Sharif S, Ghahremani MH, Soleimani M. Delivery of exogenous miR-124 to glioblastoma multiform cells by Wharton’s Jelly mesenchymal stem cells decreases cell proliferation and migration, and confers chemosensitivity[J]. Stem Cell Rev Rep, 2018, 14(2): 236-246.
|
| [38] |
Lan F, Qing Q, Pan Q, et al. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma[J]. Cell Oncol (Dordr), 2018, 41(1): 25-33.
|
| [39] |
Zeng A, Wei Z, Yan W, et al. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma[J]. Cancer Lett, 2018, 436: 10-21.
|
| [40] |
Yang C, Wang C, Chen X, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas[J]. Int J Cancer, 2013, 132(1): 116-127.
|
| [41] |
Ansari KI, Ogawa D, Rooj AK, et al. Glucose-based regulation of miR-451/AMPK signaling depends on the OCT1 transcription factor[J]. Cell Rep, 2015, 11(6): 902-909.
|
| [42] |
Kim R, Lee S, Lee J, et al. Exosomes derived from microRNA-584 transfected mesenchymal stem cells: novel alternative therapeutic vehicles for cancer therapy[J]. BMB Rep, 2018, 51(8): 406-411.
|
| [43] |
Wang J, Che F, Zhang J, et al. Diagnostic and prognostic potential of serum cell-free microRNA-214 in glioma[J]. World Neurosurg, 2019, 125: e1217-e1225.
|
| [44] |
Khan AR, Yang X, Fu M, et al. Recent progress of drug nanoformulations targeting to brain[J]. J Control Release, 2018, 291: 37-64.
|
| [45] |
Bronisz A, Wang Y, Nowicki MO, et al. Extracellular vesicles modulate the glioblastoma microenvironment via a tumor suppression signaling network directed by miR-1[J]. Cancer Res, 2014, 74(3): 738-750.
|
| [46] |
Munoz JL, Bliss SA, Greco SJ, et al. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity[J]. Mol Ther Nucleic Acids, 2013, 2(10): e126.
|
| [47] |
Ghaemmaghami AB, Mahjoubin-Tehran M, Movahedpour A, et al. Role of exosomes in malignant glioma: microRNAs and proteins in pathogenesis and diagnosis[J]. Cell Commun Signal, 2020, 18(1): 120.
|
| [48] |
Akers JC, Ramakrishnan V, Kim R, et al. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development[J]. PLoS One, 2013, 8(10): e78115.
|
| [49] |
Li Z, Ye L, Wang L, et al. Identification of miRNA signatures in serum exosomes as a potential biomarker after radiotherapy treatment in glioma patients[J]. Ann Diagn Pathol, 2020, 44: 151436.
|
| [50] |
Lan F, Yue X, Xia T. Exosomal microRNA-210 is a potentially non-invasive biomarker for the diagnosis and prognosis of glioma[J]. Oncol Lett, 2020, 19(3): 1967-1974.
|